PHC Corporation Biomedical Business Division (Headquarters: Minato-ku, Tokyo; President: Shinro Nakamura; hereinafter referred to as 'PHCbi') is pleased to announce that it will provide pharmaceutical companies, research facilities, and medical institutions with a large amount of frost on the inner door.
We are pleased to announce the release of -85-degreeC CFC-free ultra-low temperature freezer 'FrostLess' (Part number: MDF-DU700ZHS1-PJ) (1).
As the research and development of vaccines and cell/gene therapy advances, the demand for ultra-low temperature freezers used for long-term storage of cell samples and pharmaceuticals is increasing year by year. On the other hand, depending on the frequency of opening and closing the door of the product and the installation environment, frost may occur inside the refrigerator, which is one of the issues at the research site. According to the results of a survey (2) of academia in Japan , researchers found that defrosting work in ultra-low temperature freezers took time, and it was difficult to remove specimens from the freezer due to frost buildup inside the product. The burden of cooling tops the list of challenges associated with ultra-low temperature freezers.
The newly released 'FrostLess' greatly reduces frost build-up on the inner door and its surroundings, which has been a problem. It is a -85-degreeC CFC-free ultra-low temperature freezer that pursues ease of use and can be stored for a long time with peace of mind. By adding a vacuum insulation panel (VIP) to the conventional insulation material for the inner door and improving the insulation performance, frost buildup on the inner door has been reduced. In addition, the shape and materials of the inner door frame packing have been revamped to further improve heat insulation performance, greatly suppressing the formation of frost, including the formation of frost around the packing. As a result, researchers can reduce the frequency of work required for defrosting and shorten the work time by up to about 60% (4) compared to conventional models (3) , reducing the work burden at the research site. and contribute to more efficient research activities.
In addition, we have utilized unique technologies such as a new inverter compressor and dual refrigeration inverter control (5) that can reduce power consumption by using natural refrigerant with high energy efficiency and efficient rotation control in the low speed range to reduce power consumption per day. Power consumption has been reduced to 7.1kWh (6). This represents an approximately 32% reduction in power consumption compared to conventional models (7
Since PHCbi launched a medicinal refrigerator in Japan in 1966, we have been working on the development of a wide range of life science equipment centered on preservation and culture equipment. The purpose of this new product is to expand the lineup of ultra-low temperature freezers, one of the company's mainstay products, and to realize the PHC Group's medium-term management plan 'Value Creation Plan (FY22-FY25)' (8). Promote.
Shinro Nakamura, President and CEO of PHC Corporation and General Manager of the Biomedical Business Division, said, 'PHCbi launched an ultra-low temperature freezer in Japan in 1977. Since then, we have improved the quality and performance of our products, We have been aiming to provide new value to customers in the field.The newly released ultra-low temperature freezer 'FrostLess' inherits the high energy-saving performance of the 'VIP ECO' series (9) while minimizing frost generation . This is a new product that tackles the long-standing problem of suppressing the amount of heat generated.We expect that this product will not only protect valuable research samples, but also reduce the workload of researchers and contribute to improving the efficiency of research sites. We will continue to accurately grasp the diverse issues faced by researchers and healthcare professionals, and through the creation of innovative solutions, we will contribute to the resolution of issues in research and medical settings and the evolution of modalities.' said.
About PHC Corporation Biomedica Division>
Established in 1969, PHC Corporation is the operating subsidiary in Japan of PHC Holdings Corporation (Code No. 6523 TSE Prime), a global healthcare company. Under the business brand 'PHCbi,' the Biomedical Division, which is responsible for the life science business, provides research and medical support equipment and services such as ultra-low temperature freezers and CO2 incubators, and collaborates with scientists in approximately 110 countries and regions. We are committed to supporting researchers.
About PHC Holdings Corporation
PHC Holdings Corporation (Securities Code: 6523 TSE Prime) is a global healthcare company whose management philosophy is to create new value for all people who desire good health and contribute to the creation of a prosperous society. With subsidiaries such as PHC Corporation, Ascensia Diabetes Care Holdings, Epredia Holdings, LSI Medience Co., Ltd., and WeMex Co., Ltd., it develops, manufactures, and sells in the business areas of diabetes management, healthcare solutions, diagnostics and life sciences. , is servicing. Consolidated revenue for fiscal 2022 is 356.4 billion yen, and our products and services are used by customers in more than 125 countries and regions around the world. PHC Group is a collective term for PHC Holdings Corporation and its operating subsidiaries.
Contact:
Tel: 080-4816-3259
Email: masayo.okada@phchd.com
PHC HOLDINGS CORPORATION 
